The Øie–Tozer model of drug distribution and its suitability for drugs with different pharmacokinetic behavior

Bibliography

• Dominguez R. Studies of renal excretion of clearance: II. Volume of distribution. Proc Soc Exp Biol Med 1934;31:1146-50
   Google Scholar
• Atkinson AJ Jr, Lalonde RL. Introduction of quantitative methods in pharmacology and clinical pharmacology: a historical overview. Clin Pharmacol Ther 2007;82:3-6
   PubMed Web of Science ®Google Scholar
• Hochhaus G, Barrett JS, Derendorf H. Evolution of pharmacokinetics and pharmacokinetic/dynamic correlations during the 20th century. J Clin Pharmacol 2000;40:908-17
   PubMed Web of Science ®Google Scholar
• Rodgers T, Rowland M. Mechanistic approaches to volume of distribution predictions: understanding the processes. Pharm Res 2007;24:918-33
   PubMed Web of Science ®Google Scholar
• Berezhkovskiy LM. A valid equation for the well-stirred perfusion limited physiologically based pharmacokinetic model that consistently accounts for the blood-tissue drug distribution in the organ and the corresponding valid equation for the steady state volume of distribution. J Pharm Sci 2010;99:475-85
   PubMed Web of Science ®Google Scholar
• Wilkinson GR, Shand DG. A physiological approach to hepatic drug clearance. Clin Pharmacol Ther 1975;18:377-90
   PubMed Web of Science ®Google Scholar
• Gibaldi M, McNamara PJ. Apparent volumes of distribution and drug binding to plasma proteins and tissues. Eur J Clin Pharmacol 1978;13:373-80
   PubMed Web of Science ®Google Scholar
• Gibaldi M, Perrier D. Apparent volume of distribution. In: Pharmacokinetics. 2nd edition. Informa Healthcare; New York: 2007. p. 199-219
   Google Scholar
• Oie S, Tozer TN. Effect of altered plasma protein binding on apparent volume of distribution. J Pharm Sci 1979;68:1203-5
   PubMed Web of Science ®Google Scholar
• Rowland M, Peck C, Tucker G. Physiologically-based pharmacokinetics in drug development and regulatory science. Annu Rev Pharmacol Toxicol 2011;51:45-73
   PubMed Web of Science ®Google Scholar
• Bjorkman S. Prediction of the volume of distribution of a drug: which tissue-plasma partition coefficients are needed? J Pharm Pharmacol 2002;54:1237-45
   PubMed Web of Science ®Google Scholar
• Poulin P, Theil FP. Development of a novel method for predicting human volume of distribution at steady-state of basic drugs and comparative assessment with existing methods. J Pharm Sci 2009;98:4941-61
   PubMed Web of Science ®Google Scholar
• Berry LM, Roberts J, Be X, Prediction of V(ss) from in vitro tissue-binding studies. Drug Metab Dispos 2010;38:115-21
   PubMed Web of Science ®Google Scholar
• Valko KL, Nunhuck SB, Hill AP. Estimating unbound volume of distribution and tissue binding by in vitro HPLC-based human serum albumin and immobilised artificial membrane-binding measurements. J Pharm Sci 2011; In press
   PubMed Web of Science ®Google Scholar
• Fagerholm U. Prediction of human pharmacokinetics–evaluation of methods for prediction of volume of distribution. J Pharm Pharmacol 2007;59:1181-90
   PubMed Web of Science ®Google Scholar
• Wajima T, Fukumura K, Yano Y, Prediction of human pharmacokinetics from animal data and molecular structural parameters using multivariate regression analysis: volume of distribution at steady state. J Pharm Pharmacol 2003;55:939-49
   PubMed Web of Science ®Google Scholar
• Mager DE. Target-mediated drug disposition and dynamics. Biochem Pharmacol 2006;72:1-10
   PubMed Web of Science ®Google Scholar
• Benet LZ, Hoener BA. Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther 2002;71:115-21
   PubMed Web of Science ®Google Scholar
• Lombardo F, Obach RS, Shalaeva MY, Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data. J Med Chem 2002;45:2867-76
   PubMed Web of Science ®Google Scholar
• Hosea NA, Collard WT, Cole S, Prediction of human pharmacokinetics from preclinical information: comparative accuracy of quantitative prediction approaches. J Clin Pharmacol 2009;49:513-33
   PubMed Web of Science ®Google Scholar
• Waters NJ, Lombardo F. Use of the Oie-Tozer model in understanding mechanisms and determinants of drug distribution. Drug Metab Dispos 2010;38:1159-65
   PubMed Web of Science ®Google Scholar
• Do Jones R, Jones HM, Rowland M, PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 2: comparative assessment of prediction methods of human volume of distribution. J Pharm Sci 2011; In press
   Web of Science ®Google Scholar
• Stepensky D. Use of unbound volumes of drug distribution in pharmacokinetic calculations. Eur J Pharm Sci 2011;42:91-8
   PubMed Web of Science ®Google Scholar
• Aarons L. Kinetics of drug-drug interactions. Pharmacol Ther 1981;14:321-44
   PubMed Web of Science ®Google Scholar
• Aarons LJ, Rowland M. Kinetics of drug displacement interactions. J Pharmacokinet Biopharm 1981;9:181-90
   PubMedGoogle Scholar
• Hoffman A, Stepensky D. Pharmacodynamic aspects of modes of drug administration for optimization of drug therapy. Crit Rev Ther Drug Carrier Syst 1999;16:571-639
   PubMed Web of Science ®Google Scholar
• Hammarlund-Udenaes M. Active-site concentrations of chemicals - are they a better predictor of effect than plasma/organ/tissue concentrations? Basic Clin Pharmacol Toxicol 2010;106:215-20
   PubMed Web of Science ®Google Scholar
• Schmidt S, Gonzalez D, Derendorf H. Significance of protein binding in pharmacokinetics and pharmacodynamics. J Pharm Sci 2010;99:1107-22
   PubMed Web of Science ®Google Scholar
• Berezhkovskiy LM. On the influence of protein binding on pharmacological activity of drugs. J Pharm Sci 2010;99:2153-65
   PubMed Web of Science ®Google Scholar
• Csajka C, Verotta D. Pharmacokinetic-pharmacodynamic modelling: history and perspectives. J Pharmacokinet Pharmacodyn 2006;33:227-79
   PubMed Web of Science ®Google Scholar
• Danhof M, de Jongh J, De Lange EC, Mechanism-based pharmacokinetic-pharmacodynamic modeling: biophase distribution, receptor theory, and dynamical systems analysis. Annu Rev Pharmacol Toxicol 2007;47:357-400
   PubMed Web of Science ®Google Scholar
• Alvan G, Paintaud G, Wakelkamp M. The efficiency concept in pharmacodynamics. Clin Pharmacokinet 1999;36:375-89
   PubMed Web of Science ®Google Scholar
• Wright JD, Boudinot FD, Ujhelyi MR. Measurement and analysis of unbound drug concentrations. Clin Pharmacokinet 1996;30:445-62
   PubMed Web of Science ®Google Scholar
• Dasgupta A. Usefulness of monitoring free (unbound) concentrations of therapeutic drugs in patient management. Clin Chim Acta 2007;377:1-13
   PubMed Web of Science ®Google Scholar
• Pilari S, Huisinga W. Lumping of physiologically-based pharmacokinetic models and a mechanistic derivation of classical compartmental models. J Pharmacokinet Pharmacodyn 2010;37:365-405
   PubMed Web of Science ®Google Scholar
• Poulin P, Ekins S, Theil FP. A hybrid approach to advancing quantitative prediction of tissue distribution of basic drugs in human. Toxicol Appl Pharmacol 2011;250:194-212
   PubMed Web of Science ®Google Scholar
• Wada DR, Drover DR, Lemmens HJM. Determination of the distribution volume that can be used to calculate the intravenous loading dose. Clin Pharmacokinet 1998;35:1-7
   PubMed Web of Science ®Google Scholar
• Berezhkovskiy LM. The connection between the steady state (Vss) and terminal (Vbeta) volumes of distribution in linear pharmacokinetics and the general proof that Vbeta >/= Vss. J Pharm Sci 2007;96:1638-52
   PubMed Web of Science ®Google Scholar
• Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 2008;84:548-58
   PubMed Web of Science ®Google Scholar
• Mahmood I, Green MD. Pharmacokinetic and pharmacodynamic considerations in the development of therapeutic proteins. Clin Pharmacokinet 2005;44:331-47
   PubMed Web of Science ®Google Scholar
• Rowland M, Tozer TN. Dose and time dependencies. In: Clinical pharmacokinetics: concepts and applications. 3rd edition. Lippincott Williams & Wilkins; Philadelphia; 1995. p. 394-423
   Google Scholar
• Roberts DM, Buckley NA. Pharmacokinetic considerations in clinical toxicology: clinical applications. Clin Pharmacokinet 2007;46:897-939
   PubMed Web of Science ®Google Scholar
• Hoffman A, Stepensky D, Ezra A, Mode of administration-dependent pharmacokinetics of bisphosphonates and bioavailability determination. Int J Pharm 2001;220:1-11
   PubMed Web of Science ®Google Scholar
• Karlsson MO, Molnar V, Freijs A, Pharmacokinetic models for the saturable distribution of paclitaxel. Drug Metab Dispos 1999;27:1220-3
   PubMed Web of Science ®Google Scholar
• Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998;26:1-10, quiz 1-2
   PubMed Web of Science ®Google Scholar
• Yan X, Mager DE, Krzyzanski W. Selection between Michaelis-Menten and target-mediated drug disposition pharmacokinetic models. J Pharmacokinet Pharmacodyn 2010;37:25-47
   PubMed Web of Science ®Google Scholar
• Harashima H, Mamiya M, Yamazaki M, Kinetic modeling of ouabain tissue distribution based on slow and saturable binding to Na,K-ATPase. Pharm Res 1992;9:1607-11
   PubMed Web of Science ®Google Scholar
• Grover A, Benet LZ. Effects of drug transporters on volume of distribution. AAPS J 2009;11:250-61
   PubMed Web of Science ®Google Scholar
• Berezhkovskiy LM. On the possibility of self-induction of drug protein binding. J Pharm Sci 2010;99:4400-5
   PubMed Web of Science ®Google Scholar
• Levy G. Pharmacologic target-mediated drug disposition. Clin Pharmacol Ther 1994;56:248-52
   PubMed Web of Science ®Google Scholar
• Thurber GM, Schmidt MM, Wittrup KD. Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance. Adv Drug Deliv Rev 2008;60:1421-34
   PubMed Web of Science ®Google Scholar
• Li SD, Huang L. Pharmacokinetics and biodistribution of nanoparticles. Mol Pharm 2008;5:496-504
   PubMed Web of Science ®Google Scholar
• Ruenraroengsak P, Cook JM, Florence AT. Nanosystem drug targeting: Facing up to complex realities. J Control Release 2010;141:265-76
   PubMed Web of Science ®Google Scholar
• Maeda H. Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects. Bioconjug Chem 2010;21:797-802
   PubMed Web of Science ®Google Scholar
• Pang KS, Durk MR. Physiologically-based pharmacokinetic modeling for absorption, transport, metabolism and excretion. J Pharmacokinet Pharmacodyn 2010;37:591-615
   PubMed Web of Science ®Google Scholar
• Qin S, Seo JW, Zhang H, An imaging-driven model for liposomal stability and circulation. Mol Pharm 2010;7:12-21
   PubMedGoogle Scholar
• Howell BA, Chauhan A. A physiologically based pharmacokinetic (PBPK) model for predicting the efficacy of drug overdose treatment with liposomes in man. J Pharm Sci 2010;99:3601-19
   PubMed Web of Science ®Google Scholar
• Derendorf H, Meibohm B. Modeling of pharmacokinetic/pharmacodynamic (PK/PD) relationships: concepts and perspectives. Pharm Res 1999;16:176-85
   PubMed Web of Science ®Google Scholar
• Gabrielsson J, Green AR, Van der Graaf PH. Optimising in vivo pharmacology studies–Practical PKPD considerations. J Pharmacol Toxicol Methods 2010;61:146-56
   PubMed Web of Science ®Google Scholar
• Berezhkovskiy LM. On the accuracy of estimation of basic pharmacokinetic parameters by the traditional noncompartmental equations and the prediction of the steady-state volume of distribution in obese patients based upon data derived from normal subjects. J Pharm Sci 2011;100(6):2482-97
   Web of Science ®Google Scholar
• PBPK of Diazepam, IV and oral dosing. Available from: http://dougneubauer.com/pbpkdiazepam/ [Accessed 6 February 2011]
   Google Scholar